| Therapeutic | Gevokizumab |
| Target | IL1B |
| Heavy Chain | QVQLQESGPGLVKPSQTLSLTCSFSGFSLSTSGMGVGWIRQPSGKGLEWLAHIWWDGDESYNPSLKSRLTISKDTSKNQVSLKITSVTAADTAVYFCARNRYDPPWFVDWGQGTLVTVSS |
| Light Chain | DIQMTQSTSSLSASVGDRVTITCRASQDISNYLSWYQQKPGKAVKLLIYYTSKLHSGVPSRFSGSGSGTDYTLTISSLQQEDFATYFCLQGKMLPWTFGQGTKLEIK |
| 100% seqID Fv Structure | 4g6k [Fvs: HL], 4g6m [Fvs: HL] |
| 99% seqID Fv Structure | None |
| 95-98% seqID Fv Structure | None |
| 100% seqID Structure | 4g6k [Fvs: HL] |
| 100% seqID Structure | 4g6m [Fvs: HL] |
Follow these links to our prediction tools:
| Format | Whole mAb |
| Isotype | G2 |
| Highest Clinical Trial (June '19) | Phase-III |
| Estimated Status (June '19) | Active |
| Recorded Developmental Technology | na |
| INN Year Proposed | 2010 |
| INN Year Recommended | 2011 |
| Companies Involved | IRIS, National Eye Institute, North Shore-Long Island Jewish Health System, Novartis, Servier, University of Zurich, XOMA |
| Conditions Approved | na |
| Conditions Active | Uveitis, Acne vulgaris, Acute coronary syndromes, Diabetic nephropathies, Giant cell arteritis, Labyrinthitis, Myositis, Osteoarthritis, Schnitzler syndrome, Scleritis, Colorectal cancer, Renal cell carcinoma |
| Conditions Discontinued | Rheumatoid arthritis, Cancer, Gout, Juvenile rheumatoid arthritis, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Pyoderma |
| Notes |
